Insider Buying: Vivani Medical (NASDAQ:VANI) Insider Buys $19,600.00 in Stock

Vivani Medical, Inc. (NASDAQ:VANI) insider Donald Dwyer bought 20,000 shares of the stock in a transaction dated Thursday, November 12th. The shares were purchased at an average cost of $0.98 per share, for a total transaction of $19,600.00. Following the completion of the transaction, the insider directly owned 75,000 shares of the company’s stock, valued at $73,500. This trade represents a 36.36% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Vivani Medical Trading Up 2.7%

Shares of VANI stock traded up $0.03 during trading on Friday, reaching $1.01. 368,707 shares of the company’s stock traded hands, compared to its average volume of 256,490. The firm’s 50-day moving average is $1.18 and its 200 day moving average is $1.24. The company has a market capitalization of $91.10 million, a P/E ratio of -3.16 and a beta of 2.51. Vivani Medical, Inc. has a 1 year low of $0.80 and a 1 year high of $1.66.

Vivani Medical (NASDAQ:VANI) last announced its quarterly earnings results on Wednesday, November 11th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01.

Analysts Set New Price Targets

A number of analysts have recently weighed in on VANI shares. Wall Street Zen cut Vivani Medical from a “hold” rating to a “sell” rating in a research report on Saturday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, October 2nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $3.75.

About Vivani Medical

Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.